BridgeBio secures $1.25bn for genetic therapy development

BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.

Jan 19, 2024 - 18:00

BridgeBio secures $1.25bn for genetic therapy development

BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.

Read the original article

Tags:

Previous Article

FDA grants fast track designation for Verastem’s NSCLC therapy

argenx’s VYVDURA gains approval in Japan for gMG treatment

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy

STAT+: Startup BioAge raises $170 million Series D for ...

Feb 13, 2024

Gilead acquires CymaBay Therapeutics for $4.3bn

Gilead acquires CymaBay Therapeutics for $4.3bn

Mar 26, 2024

BioMarin appeases an activist

BioMarin appeases an activist

Dec 21, 2023